Soleno Therapeutics(US:SLNO) Globenewswireยท2025-11-14 15:05Core Viewpoint - Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Soleno Therapeutics, Inc., focusing on whether the company and its executives made false or misleading statements or failed to disclose material information to investors [1]. Company Overview - Soleno Therapeutics announced FDA approval for VYKAT XR (diazoxide choline) extended-release tablets on March 26, 2025, for treating hyperphagia in individuals aged 4 and older with Prader-Willi syndrome [3]. Recent Developments - During a quarterly earnings call on November 4, 2025, Soleno disclosed that the discontinuation rate of VYKAT XR due to adverse effects was approximately 8% at the end of Q3 2025. The CEO acknowledged a disruption in the product's launch trajectory following a short seller report in mid-August, which led to a decrease in start forms and an increase in discontinuations for non-serious adverse events. Following this announcement, Soleno's share price dropped by over 26% [4].